Regenxbio dealt win by appeals court in patent spat with Sarepta
Source: SeekingAlpha
2026-02-20 11:53:55 ET
More on Regenxbio, Sarepta Therapeutics
- Regenxbio: Cautiously Bullish After FDA Setbacks
- REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away
- Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy - Slideshow
- Regenxbio stock drops on FDA setback for RGX-121 gene therapy
- REGENXBIO falls after FDA clinical hold on gene therapies
Read the full article on Seeking Alpha
For further details see:
Regenxbio dealt win by appeals court in patent spat with Sarepta
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
-1.75% G/L:
$16.67 Last:
898,612 Volume:
$17.47 Open:
SRPT Latest News
February 27, 2026 09:00:00 am
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
